Stem Cell Mobilization by G-CSF Post Myocardial Infarction to Promote Myocyte Repair - Full Text View

Sponsors and Collaborators:	University of Ottawa Canadian Institutes of Health Research (CIHR)
Information provided by:	University of Ottawa
ClinicalTrials.gov Identifier:	NCT00394498

Purpose

Eighty-six patients with heart attacks will be identified at our hospital. Post heart attack we will assess heart function, blood flow to the heart, and heart cell function. We will assess these parameters using nuclear cardiology scans that are used in everyday cardiology practice. The patients will then be divided into 2 groups. One group will receive a medication called G-CSF and the other group will receive a placebo. We will give this drug (1-2ml) for 4 days beneath the skin. We will take the patients blood during this time and measure how the drug affected their blood. The patients will all have the nuclear cardiology tests again in 6 weeks and 6 months to see how their heart is functioning. As well, they will have a six month angiogram. All the patients will otherwise receive optimal care from their Cardiologist. They will be seen at 6, 12, 24, and 52 weeks to assess them clinically.

This study will test the effects of G-CSF on the heart function of patients who have had a heart attack. It is a medication that that has been shown in an animal model to improve heart function after a heart attack. It is a medication that has been used for many years to treat patients with cancers and to increase the number of cells donated by healthy bone marrow donors. It has no serious side effects. It works by increasing the number of a person’s own stem cells in the blood. Stem cells are special cells that are present in our bodies that have the ability to form new cells. It had been thought that the heart could not make new cells after it has been damaged. Other investigators have shown that this might not be the case. It is now thought that after an injury, stem cells from the bone marrow can transform into cells of the injured tissue. Therefore, we are trying to increase the number of stem cells in the circulation with G-CSF so as to increase repair in the heart after it has been damaged. This strategy has never been tried in human beings and if successful could greatly reduce death and suffering from heart disease.

Condition	Intervention	Phase
Myocardial Infarction	Drug: Granulocyte Colony Stimulating Factor	Phase II Phase III

MedlinePlus related topics: Heart Attack

Drug Information available for: Granulocyte-macrophage colony-stimulating factor Sargramostim Granulocyte colony-stimulating factor

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study
Official Title:	Stem Cell Mobilization by G-CSF by Granulocyte Colony Stimulating Factor Post Myocardial Infarction to Promote Myocyte Repair

Further study details as provided by University of Ottawa:

Primary Outcome Measures:

6 month Left ventricular ejection fraction

Secondary Outcome Measures:

6 week left ventricular ejection fraction
6 week myocardial FDG-PET uptake
6 week myocardial Ammonia-PET perfusion
6 week/month left ventricular diastolic volume
6 week/month left ventricular systolic volume

Estimated Enrollment:	86
Study Start Date:	September 2005
Estimated Study Completion Date:	October 2006

Eligibility

Ages Eligible for Study:	40 Years to 75 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Large anterior wall ST elevation AMI defined by: Post AMI LVEF less than 45% as assessed by echocardiography. It is standard practice at our institution to obtain echocardiograms on such patients before day 4 post AMI.
Age between 40 -75 years
Angiographically patent infarct related artery (IRA) with TIMI 3 flow with no significant stenosis (>70% diameter stenosis in non-intervened upon arteries or >30% in arteries that had PTCA), no dissection or visible thrombus, and considered at low risk for re-occlusion by the Cardiologist performing the coronary angiography. In patients who have undergone PTCA, this assessment will be none on a post PTCA angiogram. This will be the majority of patients.
Eligible for treatment with G-CSF within the 5 days Post AMI.

Exclusion Criteria:

Prior STEMI
Patients with regional wall motion abnormalities in the non-infarct region
Prior CABG or need for CABG
Patients with significant valve disease; defined as stenosis or regurgitation graded as greater than moderate (2+).
Patients with clinically apparent, concurrent infection, requiring intravenous antibiotics
Patients who are or could be pregnant
Patients with another etiology of LV dysfunction (known/suspected non ischemic cardiomyopathy, previous anthracycline therapy, known ethanol abuse (greater than 6 oz. ethanol/day on a regular basis).

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00394498

Contacts

Contact: Chris A Glover, MD

613-761-4119

cglover@ottawaheart.ca

Locations

Canada, Ontario
University of Ottawa Heart Institute	Recruiting
Ottawa, Ontario, Canada, K1Y 4W7

Sponsors and Collaborators

University of Ottawa

Canadian Institutes of Health Research (CIHR)

Investigators

Principal Investigator:

Chris A Glover, MD

University of Ottawa Heart Institute

More Information

No publications provided

Study ID Numbers:	135287
Study First Received:	October 30, 2006
Last Updated:	October 30, 2006
ClinicalTrials.gov Identifier:	NCT00394498 History of Changes
Health Authority:	Canada: Health Canada

Keywords provided by University of Ottawa:

Myocardial Infarction
Stem Cells

Study placed in the following topic categories:

Necrosis
Heart Diseases
Myocardial Ischemia
Vascular Diseases

Ischemia
Infarction
Myocardial Infarction

Additional relevant MeSH terms:

Necrosis
Heart Diseases
Pathologic Processes
Myocardial Ischemia
Vascular Diseases

Cardiovascular Diseases
Ischemia
Infarction
Myocardial Infarction

ClinicalTrials.gov processed this record on May 07, 2009